Propofol Manufacturer Ordered to Pay $365M in Nevada Hepatitis C Case, Plans Appeal
Teva, which was ordered to pay $365 million, said in a statement that the company clearly labeled the vials as single use and that aseptic procedures should be used at all times. The company believes there is enough evidence to warrant an appeal of the court's decision.
Baxter, which was ordered to pay $144 million, said it would also submit an appeal.
Mr. Chanin's case is the first of many to reach trial after a 2006 hepatitis C outbreak at Las Vegas endoscopy clinics. The $500 million award follows more than $5 million already awarded to Mr. Chanin and his wife by the same jury, according to the report.
Read the New York Times' report about the Las Vegas hepatitis C trial.
© Copyright ASC COMMUNICATIONS 2015. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
New From Becker's ASC Review
US general anesthesia drugs market to reach $2B by 2020: 6 important trendsRead Now
- Newfound rivals: 5 reasons Blue Cross isn't a fan of Anthem's recent acquisition
- Physicians anxiously awaiting MU rule updates — 6 notes
- Debate over drug used to treat Marburg — 6 notes
- #fixEHR: Physicians voice EHR concerns — 7 key notes
- BPC calls on Congress to accelerate medical product process: 5 things to know